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inﬂuenza infectivityThe 2009 H1N1 pandemic highlights the need to better understand inﬂuenza A infectivity and antigenicity.
Relative to other recent seasonal H1N1 inﬂuenza strains, the 2009 H1N1 virus grew less efﬁciently in eggs,
which hindered efforts to rapidly supply vaccine. Using lentiviral pseudotypes bearing inﬂuenza
hemagglutinin (HA-pseudotypes) we evaluated a glutamine to arginine mutation at position 223 (Q223R)
and glycosylation at residue 276 in HA for their effects on infectivity and neutralization. Q223R emerged
during propagation in eggs and lies in the receptor binding site. We found that the Q223R mutation greatly
enhanced infectivity of HA-pseudotypes in human cells, which was further augmented by inclusion of the
viral neuraminidase (NA) and M2 proteins. Loss of glycosylation at residue 276 did not alter infectivity. None
of these modiﬁcations affected neutralization. These ﬁndings provide information for increasing 2009
H1N1HA-pseudotype titers without altering antigenicity and offer insights into receptor use.29, Room 532, 29 Lincoln Dr.,
).
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In April 2009 the Centers for Disease Control and Prevention (CDC)
of the United States of America identiﬁed novel swine-origin
inﬂuenza A virus (H1N1) in humans. Due to sustained human to
human transmission of this virus in several geographic regions, on
June 11, 2009, the World Health Organization declared that an
inﬂuenza pandemic was under way (WHO, 2009c). This novel H1N1
virus, referred to as the 2009 pandemic H1N1 virus (2009 H1N1), has
a hemagglutinin (HA) of classical swine lineage viruses that have
circulated in the swine population for decades with little change in HA
antigenicity (Garten et al., 2009). However, it is antigenically different
from those of human seasonal inﬂuenza H1N1 viruses.
Changes in the receptor binding site (RBS) and glycosylation of HA
could alter antigenicity and virus growth (reviewed in Skehel and
Wiley, 2000). Although 2009 H1N1 viruses only replicate in
respiratory tract tissues in ferrets, they can cause infection deep in
lung tissues in animals and induce greater pathology than typical
seasonal inﬂuenza viruses (Itoh et al., 2009; Maines et al., 2009;
Munster et al., 2009), suggesting that 2009 H1N1 HA may bindreceptors differently compared to recent seasonal inﬂuenza strains
(Childs et al., 2009; Maines et al., 2009; Soundararajan et al., 2009).
Inﬂuenza viruses frequently adapt to growth on host cells by
acquiring mutations in the RBS (reviewed in Skehel and Wiley,
2000). Recently it was reported that 2009 H1N1 acquired several
mutations in the RBS during growth on eggs, including a glutamine to
arginine substitution at position 223 (Q223R) (Chen et al., 2010). In
addition, 223R is present in several vaccine candidate strains
developed for production in eggs (WHO, 2009b) and has been
identiﬁed in a clinical isolate (Potdar et al., 2010). We also found that
A/Mexico/4108/2009 virus acquired a Q223R mutation during
passage in eggs, suggestive of changes in receptor binding.
Previously we developed H1N1 lentiviral pseudotypes bearing
HA on their surface (HA-pseudotypes) for use in microneutraliza-
tion assays. HA-pseudotypes infect cells only once and lack
infectious genomes, so they are safe to use in most lab settings
because they cannot replicate. For typical H1N1 and H3N2 HA,
which lack the polybasic cleavage site, expression of human airway
trypsin-like protease (HAT) or human transmembrane protease
serine 2 (TMPRRS2) proteases during pseudotype production leads
to efﬁcient processing of HA (Wang et al., 2008). This cleavage of
HA activates the fusion potential needed for release of the viral core
into cells. In this study we evaluated the role of a mutation at 223
in the RBS and glycosylation at N276 in 2009 H1N1 HA in
pseudovirus infection and neutralization and identiﬁed conditions
for producing high-infectivity 2009 H1N1 pseudotypes that do not
alter antigenicity.
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Factors affecting 2009 H1N1 HA-pseudotype infectivity
Wild-type A/California/04/2009 (Cal/04/09) HA-pseudotypes
were initially produced in the presence of HAT and bacterial
neuraminidase (NA), as described previously (Wang et al., 2008).
However, using our standard inoculum of 15 ng of capsid protein
(p24), the infectivity of Cal/04/09 HA-pseudotypes proved to be less
than 1% of the infectivity of the control A/Puerto Rico/8/1934 (PR8)
HA-pseudotype (Fig. 1A) and other HA-pseudotypes that we
investigated in our earlier study (Wang et al., 2008). Because co-
expression of M2 and viral NA was reported to improve titers of H7/
Rostock HA-pseudotypes (McKay et al., 2006), we investigated
making Cal/04/09 HA-pseudotypes containing viral M2 and NA
proteins. As shown in Fig. 1B, compared to bacterial NA, viral NA
slightly improved HA-pseudotype infectivity, but the combination of
viral M2 and NA improved infectivity approximately 12-fold.
Nonetheless, the 2009 H1N1 HA-pseudotype infectivity still remained
relatively low compared to PR8 HA-pseudotypes. Similar results were
obtained with A/Texas/05/2009 (Tex/05/09) and A/Mexico/4108/
2009 (Mex/4108/09) HA-pseudotypes (data not shown). Co-expres-
sion of NA and M2 had no signiﬁcant effect on PR8 HA-pseudotype
infectivity (Fig. 1B). Incorporation of the 2009 H1N1 HA into
pseudotypes was not signiﬁcantly affected by the presence of viral
NA andM2 (Fig. 1C), suggesting that the enhancement of infectivity of
the 2009 H1N1 HA-pseudotypes by viral NA andM2was not due to an
increase in HA spike density.
HA often acquires adaptive mutations in the RBS after growing on
host cells (reviewed in Skehel and Wiley, 2000). We noted that aFig. 1. Co-expression of 2009 H1N1 NA and M2 improves 2009 H1N1 HA-pseudotype
infectivity. (A) Infectivity of Cal/04/09 and PR8 HA-pseudotypes using bacterial NA
from Vibrio cholerae. (B) Infectivity of Cal/04/09 (left panel) and PR8 (right panel) HA-
pseudotypes produced by using bacterial NA from V. cholerae or expression of viral NA
from Cal/04/09, with or without co-expression of Cal/04/09 M2. Results are expressed
as the mean±SD of three independent experiments using at least two different HA-
pseudotype stocks. (C) HA Western blot of Cal/04/09 HA-pseudotypes in (B), probed
with rabbit H1 HA1 antiserum. NAexo: exogenous bacterial NA from V. cholerae; NA:
viral NA from Cal/04/09.Q223R mutation (Q226R according to H3 HA numbering) emerged in
some of our 2009 H1N1 cultures during growth in eggs. This adaptive
mutation has been seen in past seasonal inﬂuenza H3N2 (Skehel and
Wiley, 2000; Stevens et al., 2010) and H1N1 strains (Q. Xu et al.,
2010). It was also seen by others in 2009 H1N1 strains following
growth on eggs (Chen et al., 2010; WHO, 2009b). Cal/04/09 HA
containing the Q223R mutation was then incorporated into pseudo-
types bearing Cal/04/09 NA and M2 proteins. Compared to the wild-
type HA-pseudotypes containing similar units of capsid protein
(15 ng/ml of p24) the Q223R HA-pseudotypes with NA and M2
further increased infectivity about 7-fold (Fig. 2A). The Q223R
mutation similarly increased the infectivity of Tex/05/09 and Mex/
4108/09 HA-pseudotypes with NA and M2 approximately 10-fold
(Fig. 2A). Co-expression of Cal/04/09 NA alone slightly improved
infectivity of Mex/4108/09 Q223R HA-pseudotype, but the combi-
nation of viral NA and M2 again synergized to give the greatest
enhancement (Fig. 2B), similar to Cal/04/09 HA-pseudotypes. Despite
the enhancement of infectivity by the Q223R substitution and co-
expression of viral NA and M2, the infectivity of Mex/4108/09 HA-
pseudotypes was still only about 16% of PR8 HA-pseudotypes.
We noted that Mex/4108/09 HA-pseudotypes consistently had
the highest infectivity, while Cal/04/09 HA-pseudotypes consistently
had the lowest (Fig. 2A). Because there is only one residue different
between the HA of Mex/4108/09 and Tex/05/09 (Fig. 2C), it appears
that that the isoleucine at position 427 in Mex/4108/09, compared to
valine found in Tex/05/09, plays an important role in its higher
infectivity (Fig. 2D). For Cal/04/09 HA-pseudotype, although V427I
mutation improves infectivity, it is still signiﬁcantly lower than that of
Mex/4108/09 (Fig. 2D). Comparing HA for Tex/05/09 and Cal/04/09,
there are three residues different at positions 83, 197, and 321 of HA
(Fig. 2C). However, only the threonine to alanine mutation (T197A),
but not substitutions of proline to serine at position 83 (P83S) or
isoleucine to valine at position 321 (I321V), signiﬁcantly improves the
infectivity of Cal/04/09 HA-pseudotypes to the infectivity level of
Tex/05/09 HA-pseudotypes (Fig. 2E). This ﬁnding indicates that T197
is responsible for the lower titer of Cal/04/09 HA-pseudotypes.
N276 glycosylation of 2009 H1N1 HA has no impact on viral infectivity
The 2009 H1N1 HA has a glycosylation site at position 276 (N276,
NTT sequence) that has not been seen in recent seasonal H1N1 HA
sequences, though glycosylation sites in the vicinity of this region have
been present (Yang et al., 2010). We investigated whether the N276
glycosylation site affected infectivity of 2009 H1N1 HA-pseudotypes.
When tested with the H1N1 Cal/04/09 strain in the presence of viral
NA and M2, HA-pseudotypes with a glutamine to aspartic acid
substitution at position 276 (N276D) showed similar infectivity as
wild-type HA-pseudotypes (Fig. 3A), in agreement with studies
involving replicating virus in eggs (Chen et al., 2010). Similar results
were seenwith Tex/05/09 andMex/4108/09 strains (data not shown).
HA expression and processing were also not affected (Fig. 3B), and the
N276D mutation has no impact on the infectivity of 2009 H1N1 HA-
pseudotypes bearing the Q223R mutation (data not shown).
Q223R and N276 do not change 2009 H1N1 HA antigenicity
We next investigated the impact of the glycosylation site and RBS
mutations on neutralization. HA-pseudotypes for Cal/04/09, Tex/05/
09, and Mex/4108/09 were tested against a panel of H1N1 antisera
(Table 1). Ferret antisera against 2009 H1N1 Cal/04/09 HA, but not
the seasonal inﬂuenza HA (NCD/20/99, SI/03/06 and Bris/59/07)
neutralized all 2009 H1N1 HA-pseudotypes with similar titers.
Hyperimmunized sheep antisera against seasonal inﬂuenza HA
showed a lower level of neutralization that was similar for all 2009
H1N1 HA-pseudotypes, though the sheep antisera against 2009 H1N1
Cal/07/09 HA was the most potent. The identical neutralization titers
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Fig. 2. Effect of the Q223R mutation and strain difference on HA-pseudotype infectivity. (A) Q223R mutation improves 2009 H1N1 HA-pseudotype infectivity in all three 2009 H1N1
HA-pseudotypes bearing viral NA and M2 from Cal/04/09. (B) Infectivity of Mex/4108/09 HA-pseudotypes with Q223R mutation produced using bacterial NA from Vibrio cholerae
or with expression of viral NA from Cal/04/09, with or without co-expression of Cal/04/09M2. (C) Sequence comparison of HAs fromMex/4108/09, Tex/05/09 and Cal/04/09 was
performed by the ClustalW program. The different residues among these HAs are indicated (grey). (D) V427I improves Tex/05/09 and Cal/04/09 HA-pseudotype infectivity. (E)
T197A, but not P83S and I321V improves Cal/04/09 HA-pseudotype infectivity. All results are expressed as the mean±SD of three independent experiments using at least two
different HA-pseudotype stocks. Tex: Tex/05/09; Mex: Mex/4108/09; Cal: Cal/04/09; NAexo: Exogenous bacterial NA from V. cholerae; NA: viral NA from Cal/04/09.
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cate that HAs of Cal/04/09, Tex/05/09 and Mex/4108/09 have
similar antigenicities, as previously reported (Quan et al., 2010;WHO,HA0
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Fig. 3. N276 glycosylation has no impact on HA processing and HA-pseudotype
infectivity. (A) Infectivity of wild-type and N276D mutant Cal/04/09 HA-pseudotypes
produced with co-expression of Cal/04/09 NA and M2. Results are expressed as the
mean±SD of three independent experiments using at least two different HA-
pseudotype stocks. (B) HA Western blot of wild-type and N276D mutant Cal/04/09
HA-pseudotypes, probed with rabbit H1 HA1 antiserum.2009a). Importantly, neutralization of HA-pseudotypes with the
Q223R mutation also gave similar titers as wild type (Table 2). Thus,
the Q223R mutation in the RBS greatly improves infectivity of HA-
pseudotypes in human cells without changing HA antigenicity.
Neutralization titers of Q223R HA-pseudotypes were also not affected
by N276 glycosylation (Table 2). Both Q223R and N276 glycosylation
were also recently reported as not affecting HA antigenicity of a cold
adapted live-attenuated H1N1 virus (Chen et al., 2010). Some egg-
grown candidate 2009 H1N1 vaccine strains also contain the Q223R
mutation (WHO, 2009b), indicating that Q223R does not negatively
impact antigenicity. The concordant infectivity and antigenicity
results between HA-pseudotypes and replicating virus grown in
eggs demonstrate that HA-pseudotypes can be useful for investigating
HA mutations relevant for vaccine selection.
We next veriﬁed that the presence of viral NA with M2 in HA-
pseudotypes did not affect neutralization. Q223R HA-pseudotypes
bearing viral NA were compared to pseudotypes lacking viral NA but
supplemented with bacterial NA in trans to release pseudotypes into
the culture medium. Both pseudotype stocks gave similar titers
against all ferret serum samples (Table 2), consistent with the
expectation that NA neutralization primarily affects viral release from
infected cells (Johansson et al., 1989, 1993; Qiu et al., 2006; Subbarao
et al., 2006).
Table 1
Comparison of neutralization titers for 2009 H1N1 HA-pseudotypes. The 2009 H1N1 Mexico/4108/09, Texas/05/09, and California/04/09 HA-pseudotypes were evaluated for
neutralization by reference antisera described in Table 3. The 95% neutralization (IC95) titers represent at least duplicate testing.
HA-pseudotypes HA subtype and HA antiserum source
Ferret antiserum Sheep antiserum
Cal/04/09 NCD/20/99 SI/03/06 Bris/59/07 CA/07/09 NCD/20/99 SI/03/06 Bris/59/07
Mex/4108/09 10478 b80 b80 b80 173358 583 2237 20480
Tex/05/09 10180 b80 b80 b80 217942 446 2453 18556
Cal/04/09 12446 b80 b80 b80 193850 496 1849 21974
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To gain insights into the possible consequences of the Q223R
mutation on receptor binding, wemodeled the mutation based on the
A/Darwin/2001/2009 HA structure (PDB: 3M6S) (Yang et al., 2010)
because its receptor binding site is identical to the 2009 H1N1 HAs
used in our experiments. In our model (Fig. 4), the Q223R mutation
appears to interact with the negatively charged amino acid D222 in
the RBS (Fig. 4A, right panel), forming a network between R223, K219,
D222, and E224. Such an interaction could eliminate the Q223
interaction with T133 in the wild-type HA (Fig. 4A, left panel), leaving
a small gap between the residues 223 and 133 that could be relevant
for increased ligand binding (Fig. 4A, right panel arrow). When α2,6
sialic acid was modeled in the RBS (Fig. 4B) in HA containing either
223Q and 223R, the binding of D187, K219 and D222 toα2,6 sialic acid
appears to be similar. However, 223R appears to slightly change the
interaction of HA and α2,6 sialic acid by interacting exclusively with
the carboxyl group (Fig. 4B, circle). R223 is bulkier than Q223 and
close to the carboxyl group of sialic acid, raising the possibility that the
sugar could change its conformation to interact properly with the RBS
or that the RBS could alter its conformation to accommodate R223.
Such changes along with potential stronger interactions between the
carboxyl group of sialic acid and the positively charged 223R,
compared to 223Q, may explain the observed enhance infectivity of
the Q223R HA-pseudotypes.
Discussion
HA-pseudotypes provide a rapid and safe tool for analyzing HA
function and antigenicity without the need for working with live virus
(Alberini et al., 2009; Kong et al., 2006; Nefkens et al., 2007;
Temperton et al., 2007; Wang et al., 2008). Our studies show that
wild-type 2009 H1N1 HA-pseudotype infectivity is extremely low in
human 293T cells but can be improved up to 100-fold by co-
expression of viral NA and M2 proteins and the introduction of the
Q223R mutation in HA. The Q223R substitution does not affect
neutralization of HA-pseudotypes in human cells, in agreement with
results involving virus grown in eggs (Chen et al., 2010;WHO, 2009b).Table 2
The impact of NA, Q223R and glycosylation at residue N276 on neutralization titer. The
impact of NA, Q223R and glycosylation at residue N276 on neutralization and HA
antigenicity was evaluated with Mex/4108/09 HA-pseudotypes. HA antiserum titers
(IC95) reported were from at least duplicate testing of reference antisera (two-fold
serially diluted).
Serum samples Neutralization titers
Viral NA Exogenous NA
HA-
WT
HA-
Q223R
HA-
N276D
HA-Q223R
Ferret antiserum (Cal/04/09) 10478 10265 10504 10387
Ferret antiserum (Cal/07/09) 17125 16922 16780 17006
Ferret antiserum (NCD/20/99) b80 b80 b80 b80
Ferret antiserum (SI/03/06) b80 b80 b80 b80
Ferret antiserum (Bris/59/07) b80 b80 b80 b80
Viral NA: Cal/04/09 NA; Exogenous NA: Vibrio cholerae NA.These modiﬁcations make the 2009 H1N1 HA-pseudotypes well
suited for neutralization studies.
The 223 position has previously been identiﬁed as playing a role
in receptor preferences in other inﬂuenza H3 and H1 strains
(Matrosovich et al., 2000; Rogers et al., 1983; Skehel and Wiley,
2000; Stevens et al., 2010; Q. Xu et al., 2010). We found the Q223R
mutation as an isolated substitution during passage of the virus in
eggs, but it was also identiﬁed as one of several egg-adapted
mutations that emerged in cultures leading to the development of
the 2009 H1N1 live-attenuated inﬂuenza vaccine (Chen et al., 2010).
In that report the Q223R variant abolishedα2,6 sialic acid binding in a
chicken red blood cell assay (Chen et al., 2010). Residues D187 and
D222 in the RBS are important for HA binding toα2,6 glycans in H1N1
infection in humans (Gamblin et al., 2004). In the 2009 H1N1 HA,
D187 and D222 were reported to be destabilized by I216 and E224
(Maines et al., 2009), which may consequently allow 2009 H1N1 HA
to also bind weakly to α2,3 glycans (Childs et al., 2009; Maines et al.,
2009; Soundararajan et al., 2009). The 293T human embryonic kidney
cells express both α2,6 and α2,3 linkage sialic acid receptors, but the
relative amounts may vary according to cell lineage (Guo et al., 2009;
Su et al., 2008). Nonetheless, α2,6 linkages are likely to predominate
in human cells. The Q223R mutation does not appear to alter the
orientation of D187 and D222 in our model, so a potential receptor
switch from α2,6 to α2,3 sialic acid is not apparent. 223R has also
been identiﬁed in a human isolate (Potdar et al., 2010). Experimental
studies are needed to elucidate how the Q223R mutation in the 2009
H1N1 HA affects receptor utilization.
The few mutations in HA that distinguish the infectivity of Mex/
4108/09, Tex/05/09 and Cal/04/09 HA-pseudotypes also provide
clues to receptor use. How I427 in Mex/4108/09 HA improves HA-
pseudotype infectivity is not clear, but the contributions of A197 in
HA-pseudotype infectivity is probably due to its inﬂuence on receptor
usage. The T197A mutation was recently shown to facilitate viral
rescue and ampliﬁcation in eggs for A/California/07/2009, especially
in conjunction with mutations at position 222 or 223 that often
contain charged mutations. In contrast, Cal/04/09, which has T197,
could not be rescued, even with charged mutation in 222 (Chen et al.,
2010). These observations suggest that A197 also contributes to HA
interactions with receptor.
Although inﬂuenza virus envelope proteins M2 and NA did not
signiﬁcantly improve infectivity of HA-pseudotypes for other H1N1
strains, the combination of viral NA and M2 unexpectedly increased
2009 H1N1 HA-pseudotype infectivity. The mechanism underlying
this synergistic enhancement is not known. While NA is critical for
efﬁcient release of virus from producer cells, it has also been
suggested that NA can play a role in entry, perhaps by desialylation
of HA (Su et al., 2009). The M2 protein is a proton-selective ion
channel that plays an important role in uncoating of inﬂuenza
ribonucleoprotein core, and, more recently, has been implicated in
facilitating formation of ﬁlamentous forms of inﬂuenza (Rossman et
al., 2010). For HA with a polybasic cleavage site, such as H7, in which
HA cleavage can occur in the exocytic pathway, the proton channel
activity of M2 may also regulate pH and protect HA from premature
pH-induced conformational changes in the trans-Golgi network
(Steinhauer et al., 1991). During the production of HA-pseudotypes,
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Fig. 4. Model of 2009 H1N1 HA receptor binding site (RBS) and interactions with the sialic acid receptor. (A) Residues and side-chain interactions of residues in RBS of wild-type
(left) and Q223R mutant (right) of 2009 H1N1 HA. (B) RBS interactions with α2,6 sialic acid (purple). Left: wild-type 2009 H1N1 HA. Right: Q223R mutant 2009 H1N1 HA. Circle
shows the difference of RBS interaction with sialic acid between wild-type and the Q223R mutation. Yellow dashed lines show potential hydrogen bonds.
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pathway (Bottcher-Friebertshauser et al., 2010), though M2 did not
signiﬁcantly affect incorporation of mature HA into the retroviral
pseudovirions (Fig. 1C). The 2009 H1N1 HA forms monomers and
aggregates when expressed as recombinant proteins (R. Xu et al.,
2010; Yang et al., 2010) and may be less stable than the HA of other
recent seasonal inﬂuenza strains. Whether misfolding of the 2009
H1N1 HA contributes to its reduced infectivity and plays a role in the
improvement of HA-pseudotype infectivity by NA and M2 requires
further study.
Assays for evaluating traditional inactivated inﬂuenza vaccines
focus on HA, without regard to the presence of NA, even though both
HA and NA antibodies can contribute to protection. HA-pseudotypes
allow measurements of HA neutralizing antibodies separate from NA
antibodies, because bacterial NA can be supplied in trans during
pseudotype production. In our studies, incorporation of viral NA into
pseudotypes did not affect neutralization. This ﬁnding is consistent
with NA antibodies playing a role primarily in preventing release of
virus from producer cells, which is not an issue for pseudotypes thatonly undergo a single-cycle infection and do not produce infectious
progeny. These ﬁndings also indicate that NA incorporation into the
HA-pseudotypes does not directly affect HA antigenicity.
In summary, glycosylation at N276 does not affect antigenicity or
infectivity, but the Q223R mutation greatly increases infectivity
without affecting antigenicity. The 2009 H1N1 HA bearing this
mutation together with viral NA and M2 produce robust HA-
pseudotypes that should be valuable tools for serological and viral
entry studies.
Materials and methods
Viruses, plasmids, and cell lines
The inﬂuenza viruses were propagated in the allantoic cavities
of 9-day-old embryonated eggs by inoculation of 0.2 ml of diluted
virus stocks containing ~104 50% egg infectious doses (EID50) or 0.1
hemagglutination units (HAU)/ml at 33 °C for 2 days. Full-length
wild-type HA ORF from A/Texas/05/2009 (GenBank GQ168861),
379W. Wang et al. / Virology 407 (2010) 374–380A/Mexico/4108/2009 (GenBank GQ223112) and A/California/04/
2009 (GenBank FJ966082) was ampliﬁed from virus by reverse
transcription-polymerase chain reaction (RT-PCR). Full-length wild-
type NA ORF from A/California/04/2009 (GenBank FJ966084) was
also ampliﬁed from virus by RT-PCR. The HA and NA ORFs were then
placed into CMV/R 8κB expression plasmid obtained from Dr. Gary J.
Nabel (National Institutes of Health (NIH), Bethesda, MD), as
described previously (Wang et al., 2008). Full-length wild-type M2
ORF of A/California/04/2009 (GenBank FJ969513) was chemically
synthesized by Integrated DNA Technologies (Coralville, IA) and
placed into pCDNA 3.1(+) (Invitrogen, Carlsbad, CA). In addition, the
glycosylation site mutation N276D, the Q223R mutation in the RBS,
and HA with mutations P83S, T197A, I321V, and V427I were
introduced using standard molecular biology protocols. Codon-
optimized HAT gene expression construct (pCAGGS-HATcop) was
described before (Wang et al., 2010) and performed similarly to the
HAT plasmid (Bottcher et al., 2006) used previously (Wang et al.,
2008). The HIV gag/pol (pCMVΔR8.2) and Luc reporter (pHR'CMV-Luc)
constructs were described previously (Naldini et al., 1996; Zufferey
et al., 1997) and obtained from Dr. Gary J. Nabel (NIH, Bethesda, MD).
The 293T cells were cultured in Dulbecco's modiﬁed eagle medium
(DMEM) with high glucose, L-glutamine, MEM non-essential amino
acids, penicillin/streptomycin and 10% fetal calf serum.
Antisera
HA antisera from ferrets infected with the inﬂuenza viruses and
hyper-immune sheep HA antisera immunized with bromelain-
cleaved HA were provided by the US Food and Drug Administration
(FDA), UK National Institute for Biological Standards and Control
(NIBSC), and Australia Therapeutic Goods Administration (TGA),
except for ferret A/California/04/2009 antiserum, which was kindly
provided by Dr. Kanta Subbarao (NIH, Bethesda, MD) and hyper-
immune ferret A/California/07/2009 HA antiserum, which was
purchased from ATCC (Table 3). Rabbit antisera against H1N1 HA1
were produced via immunization with H1N1 (NCD) HA1 peptides
(eENZYME) as described previously (Wang et al., 2008). Sera were
heat inactivated by incubation at 56 °C for 30 minutes prior to use in
neutralization assays.
Production of HA-pseudotypes
HA-pseudotypes carrying a luciferase (Luc) reporter gene were
produced in 293T cells as described previously (Wang et al., 2008).
2.5 μg of HAT and, where indicated, 2.5 μg of A/California/04/2009
M2 expression plasmids were included in the transfection. For the
release of HA-pseudotypes from cell surface of the producer cells,
either 4 μg of A/California/04/2009 NA expression plasmid was
included in transfection or 7 mU/ml of bacterial NA from Vibrio
cholerae (Sigma, St. Louis, MO) was added to the cell growth medium
at 18 h post-transfection. HA-pseudotypes were collected 48 h post-
transfection, ﬁltered through a 0.45-μm low protein binding ﬁlter, andTable 3
List of animal HA antiserum used in pseudotype studies.
Antiserum
source
Anti-HA serum
Abbreviation Full name
Ferret Cal/04/09 A/California/04/2009 (NIH)
Cal/07/09 A/California/07/2009 (ATCC)
NCD/20/99 A/New Caledonia/20/1999 (F-99-4A, FDA)
SI/03/06 A/Solomon Islands/03/2006 (2007-150, FDA)
Bris/59/07 A/Brisbane/59/2007 (2008-587, FDA)
Sheep Cal/07/09 A/California/07/2009 (09/152, NIBSC, UK)
NCD/20/99 A/New Caledonia/20/1999 (CBER S-7849 M2, FDA)
SI/03/06 A/Solomon Islands/03/2006 (CBER S-7855 M2, FDA)
Bris/59/07 A/Brisbane/59/2007 (AS396-1, TGA, Australia)used immediately or stored at−80 °C. At least two independent HA-
pseudotype stocks made from separate plasmid preparations were
used for each study. HA-pseudotype titers weremeasured by infecting
293T cells with HA-pseudotypes for 48 h prior to measuring luciferase
activity in infected cells (luciferase assay reagent, Promega) as
described previously (Wang et al., 2008). Pseudotype titers were
expressed as relative luminescence unit per milliliter of HA-
pseudotype supernatants (RLU/ml).
The HA-pseudotypes were quantiﬁed by immunoblot analysis
using rabbit HA1 antisera and HIV-1 p24 gag ELISA assay (AIDS
Vaccine Program, NCI-Frederick Cancer Research and Development
Center, Frederick, MD), as described previously (Wang et al., 2008).
HA-pseudotype neutralization assay
HA-pseudotypes containing approximately 15 ng/ml of p24
antigen were incubated with heat-inactivated serum samples for 1 h
at 37 °C, then 100 μl of pseudovirus and serum mixtures were
inoculated onto 96-well plates that were seeded with 2×104 293T
cells/well one day prior to infection. HA-pseudotype infectivity was
evaluated 48 h later by luciferase assay, as previously described
(Wang et al., 2008). The serum dilution causing a 95% reduction of
RLU compared to control (IC95-neutralizing antibody titer) was used
as the neutralization endpoint titer (Wang et al., 2010). IC95 was
calculated using Graphpad Prism software. Data reported were from
at least duplicate testing of serum samples.
Computational analysis
The RBS region of 2009 H1N1 HAwas inferred by using the Protein
Data Bank (PDB) entry 3M6S (Yang et al., 2010). The RBS interactions
with sialic acid receptor and the effect of the 223Q and 223R on
receptor binding were modeled by using 3M6S structure. The 3M6S
structure was aligned to HA structures 1RVZ and 1RVX (Gamblin et al.,
2004) that contain α2,6 and α2,3 sialic acid receptors, respectively.
Receptor coordinates were transferred to the 3M6S structure to
determine relevant interactions between the HA and the carbohy-
drates. Mutant HAs were generated by mutating the selected residues
(223Q and 223R) with the Mutator plug-in included in VMD 1.8.7
(Humphrey et al., 1996); the resulting structures were minimized by
10,000 conjugate gradient steps with NAMD 2.7 (Phillips et al., 2005).
During minimization the side chains were allowed to move while the
protein backbone was kept restrained. All images were rendered with
PyMol 0.99 (http://www.pymol.org).
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